(VIANEWS) – Shares of Pacific Biosciences of California (NASDAQ: PACB) rose by a staggering 10.91% to $11.23 at 11:23 EST on Tuesday, following the last session’s downward trend. NASDAQ is rising 2.43% to $11,468.35, following the last session’s downward trend. This seems, as yet, an all-around positive trend exchanging session today.

Pacific Biosciences of California’s last close was $10.13, 64.04% below its 52-week high of $28.17.

About Pacific Biosciences of California

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Earnings Per Share

As for profitability, Pacific Biosciences of California has a trailing twelve months EPS of $-0.34.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -43.76%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Pacific Biosciences of California’s stock is considered to be oversold (<=20).

More news about Pacific Biosciences of California (PACB).